Azher Hussain
Overview
Explore the profile of Azher Hussain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Li W, Wang Y, Lohith T, Zeng Z, Tong L, Mazzola R, et al.
Sci Transl Med
. 2022 Jan;
14(627):eabg3684.
PMID: 35020407
Positron emission tomography (PET) ligands play an important role in the development of therapeutics by serving as target engagement or pharmacodynamic biomarkers. Here, we describe the discovery and translation of...
12.
McCrea J, Hussain A, Ma B, Garrett G, Evers R, Laabs J, et al.
Clin Pharmacol Drug Dev
. 2021 Nov;
11(3):406-412.
PMID: 34821075
Gefapixant (MK-7264, AF-219), a first-in-class P2X3 antagonist, is being developed as oral treatment for refractory or unexplained chronic cough. Based on in vitro data, gefapixant exerts inhibitory activity on the...
13.
Nussbaum J, Hussain A, Ma B, Min K, Evers R, Li Y, et al.
Clin Pharmacol Drug Dev
. 2021 Jun;
11(1):123-128.
PMID: 34145987
Gefapixant (MK-7264, AF-219) is a first-in-class P2X3 antagonist in development for refractory or unexplained chronic cough. Gefapixant is primarily cleared by renal excretion. To assess the importance of the multidrug...
14.
Muccino D, Morice A, Birring S, Dicpinigaitis P, Pavord I, Assaid C, et al.
ERJ Open Res
. 2020 Dec;
6(4).
PMID: 33263037
Background: We present study designs, dose selection and preliminary patient characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough (RCC) or unexplained...
15.
Roadcap B, Hussain A, Dreyer D, Carter K, Dube N, Xu Y, et al.
Bioanalysis
. 2020 Jul;
12(13):893-904.
PMID: 32648772
In this paper we show the application of the Tasso OnDemand™, a novel automated sample collection device, in conjunction with volumetric absorptive microsampling (VAMS) for the development of gefapixant, a...
16.
Jauslin P, Kulkarni P, Li H, Vatakuti S, Hussain A, Wenning L, et al.
Clin Pharmacokinet
. 2019 Mar;
58(8):1059-1068.
PMID: 30915660
Background: Tildrakizumab is an anti-interleukin-23p19 monoclonal antibody recently approved for the treatment of chronic plaque psoriasis. Methods: This analysis characterizes the population pharmacokinetics of subcutaneous tildrakizumab and identifies covariates influencing...
17.
Khalilieh S, Hussain A, Montgomery D, Levine V, Shaw P, Bodrug I, et al.
Br J Clin Pharmacol
. 2018 Jun;
84(10):2292-2302.
PMID: 29926968
Aims: Tildrakizumab, an interleukin (IL)-23 inhibitor, is indicated for the treatment of moderate to severe chronic plaque psoriasis. Although tildrakizumab is not metabolized by, and does not alter, cytochrome P450...
18.
Lewin J, Soria J, Stathis A, Delord J, Peters S, Awada A, et al.
J Clin Oncol
. 2018 May;
36(30):3007-3014.
PMID: 29733771
Purpose: Birabresib (MK-8628/OTX015) is a first-in-class bromodomain inhibitor with activity in select hematologic tumors. Safety, efficacy, and pharmacokinetics of birabresib were evaluated in patients with castrate-resistant prostate cancer, nuclear protein...
19.
Chen N, Wang W, Fauty S, Fang Y, Hamuro L, Hussain A, et al.
MAbs
. 2014 Feb;
6(2):502-8.
PMID: 24492305
The neonatal Fc receptor (FcRn) plays a pivotal role in IgG homeostasis, i.e., it salvages IgG antibodies from lysosomal degradation following fluid-phase pinocytosis, thus preventing rapid systemic elimination of IgG....
20.
Hussain A, Gorovits B, Leal M, Fluhler E
Bioanalysis
. 2013 Dec;
6(1):21-32.
PMID: 24341492
Background: Antibody-drug conjugates (ADCs) are a new generation of anticancer therapeutics. The objective of this manuscript is to propose a methodology that can be used to assess the stability of...